Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2017

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2017

Summary

According to the recently published report Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2017; Integrin Alpha 7 (ITGA7) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies.

Integrin Alpha 7 (ITGA7) - Alpha-7 integrin is a protein encoded by the ITGA7 gene. It induces changes in the shape and mobility of myoblasts, and facilitates their localization at laminin-rich sites of secondary fiber formation. It is involved in the maintenance of the myofibers cytoarchitecture as well as for their anchorage, viability and functional integrity.

The report Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2017 outlays comprehensive information on the Integrin Alpha 7 (ITGA7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Integrin Alpha 7 (ITGA7) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase I, Preclinical and Discovery stages are 1, 4 and 4 respectively. Report covers products from therapy areas Musculoskeletal Disorders and Genetic Disorders which include indications Muscular Dystrophy and Duchenne Muscular Dystrophy.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Integrin Alpha 7 (ITGA7)
- The report reviews Integrin Alpha 7 (ITGA7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Integrin Alpha 7 (ITGA7) targeted therapeutics and enlists all their major and minor projects
- The report assesses Integrin Alpha 7 (ITGA7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Integrin Alpha 7 (ITGA7) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Integrin Alpha 7 (ITGA7)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Integrin Alpha 7 (ITGA7) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Integrin Alpha 7 (ITGA7) - Overview
Integrin Alpha 7 (ITGA7) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Integrin Alpha 7 (ITGA7) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Molecule Type
Integrin Alpha 7 (ITGA7) - Companies Involved in Therapeutics Development
Strykagen Corp
Integrin Alpha 7 (ITGA7) - Drug Profiles
Stryka-232 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stryka-234 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stryka-425 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stryka-516 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stryka-516s - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stryka-533 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stryka-969 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stryka-978 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
StrykaPro-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables


Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Strykagen Corp, H2 2017

List Of Figures


Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indications, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Integrin Alpha 5 (CD49 Antigen Like Family Member E or Fibronectin Receptor Subunit Alpha or Integrin Alpha F or VLA 5 or CD49e or ITGA5) - Drugs in Development, 2021

Integrin Alpha 5 (CD49 Antigen Like Family Member E or Fibronectin Receptor Subunit Alpha or Integrin Alpha F or VLA 5 or CD49e or ITGA5) - Drugs in Development, 2021Integrin

USD 3000 View Report

Cells Expressing Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Drugs in Development, 2021

Cells Expressing Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Drugs in Development, 2021Cells Expressing Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)

USD 3000 View Report

Integrin Alpha 5 (CD49 Antigen Like Family Member E or Fibronectin Receptor Subunit Alpha or Integrin Alpha F or VLA 5 or CD49e or ITGA5) - Drugs in Development, 2021

Integrin Alpha 5 (CD49 Antigen Like Family Member E or Fibronectin Receptor Subunit Alpha or Integrin Alpha F or VLA 5 or CD49e or ITGA5) - Drugs in Development, 2021Integrin

USD 3000 View Report

Cells Expressing Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Drugs in Development, 2021

Cells Expressing Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV) - Drugs in Development, 2021Cells Expressing Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV)

USD 3000 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available